ACAD has been the subject of a number of other research reports. Zacks Investment Research upgraded shares of ACADIA Pharmaceuticals from a hold rating to a buy rating and set a $26.00 target price for the company in a research report on Thursday, July 25th. Bank of America set a $31.00 target price on shares of ACADIA Pharmaceuticals and gave the stock a buy rating in a research report on Wednesday, July 31st. Raymond James increased their target price on shares of ACADIA Pharmaceuticals from $40.00 to $43.00 and gave the stock a strong-buy rating in a research report on Friday, May 31st. BidaskClub upgraded shares of ACADIA Pharmaceuticals from a hold rating to a buy rating in a research report on Wednesday, August 7th. Finally, JPMorgan Chase & Co. set a $32.00 target price on shares of ACADIA Pharmaceuticals and gave the stock a buy rating in a research report on Wednesday, July 31st. Three equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. ACADIA Pharmaceuticals has an average rating of Buy and an average price target of $33.91.
Shares of ACAD stock opened at $29.45 on Friday. ACADIA Pharmaceuticals has a 52-week low of $12.86 and a 52-week high of $30.38. The firm has a market cap of $4.31 billion, a PE ratio of -15.18 and a beta of 2.85. The company has a current ratio of 6.85, a quick ratio of 6.79 and a debt-to-equity ratio of 0.02. The firm has a fifty day simple moving average of $26.70.
ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its quarterly earnings data on Wednesday, July 31st. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.08. ACADIA Pharmaceuticals had a negative net margin of 101.45% and a negative return on equity of 70.97%. The company had revenue of $83.21 million during the quarter, compared to analysts’ expectations of $72.50 million. During the same quarter in the prior year, the company posted ($0.51) EPS. The business’s revenue was up 45.8% on a year-over-year basis. On average, research analysts forecast that ACADIA Pharmaceuticals will post -1.78 EPS for the current year.
Institutional investors have recently made changes to their positions in the stock. Two Sigma Advisers LP acquired a new position in ACADIA Pharmaceuticals in the fourth quarter valued at approximately $881,000. Legal & General Group Plc lifted its holdings in ACADIA Pharmaceuticals by 23.0% in the fourth quarter. Legal & General Group Plc now owns 42,147 shares of the biopharmaceutical company’s stock valued at $681,000 after acquiring an additional 7,880 shares during the last quarter. Amalgamated Bank acquired a new position in ACADIA Pharmaceuticals in the fourth quarter valued at approximately $232,000. Norges Bank acquired a new position in ACADIA Pharmaceuticals in the fourth quarter valued at approximately $15,717,000. Finally, Geode Capital Management LLC lifted its holdings in ACADIA Pharmaceuticals by 16.7% in the fourth quarter. Geode Capital Management LLC now owns 1,244,939 shares of the biopharmaceutical company’s stock valued at $20,130,000 after acquiring an additional 177,701 shares during the last quarter. Institutional investors and hedge funds own 94.83% of the company’s stock.
ACADIA Pharmaceuticals Company Profile
ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.